ALTG 15/003 DREAM: A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in

  • To determine the 6 month PFS, safety and tolerability of durvalumab in combination with cisplatin and pemetrexed in MPM planned for 1st line chemo
  • Planned sample size 54 at approx. 14 sites
  • Protocol finalised and granted central ethics approval
  • First sites opened December 2016
  • Initial safety run-in (6 patients) completed with no Dose Limiting Toxicities or SAEs reported; confirmed dose of durvaluamb 1125 mg
  • Recruitment to all sites opened in March 2017
  • 16/31 (Stage 1) patients have been recruited
State/TerritorySitePIActivation DateRecruitment
ACTCanberra HospitalDavid Leong
NSWBorder Medical OncologyCraig Underhill
Chris O'Brien LifehouseSteven Kao4 Apr 20171
Coffs Harbour Health Campus - NCCIKaren Briscoe8 Mar 2017
Nepean Cancer Care CentreCatherine Crombie
Northern Cancer Institute St LeonardsNick Pavlakis9 Dec 20161
QLDPrincess Alexandra HospitalKen O'Byrne
The Prince Charles HospitalBrett Hughes9 Dec 20164
SAFlinders Medical CentreChris Karapetis
VICAustin HospitalTom John
Peter MacRichard de Boer
WASir Charles Gairdner HospitalAnna Nowak14 Dec 201610
Other (NZ)Auckland HospitalRichard Sullivan
Canterbury Regional Cancer and Haematology ServiceDavid Gibbs

Study Contacts

Study Chair: Anna Nowak

CTC Trial Coordinator: Hannora Jurcovic

Upcoming Events

28 August 2017 12.00am TACT Board Teleconference (closed)
8 September 2017 12.00am ESMO 2017 Congress, Madrid Spain
6 October 2017 12.00am ***UPDATED*** 3rd ALTG Preceptorship in Lung Cancer, Melbourne VIC
15 October 2017 12.00am TACT General Assembly (closed), Yokohama Japan
15 October 2017 12.00am 18th WCLC, Yokohama Japan
24 November 2017 12.00am ***UPDATED*** 2017 ALTG Lung Cancer Symposium, Sydney NSW
24 November 2017 12.00am ***UPDATED*** ALTG Members’ Meeting, Sydney NSW